SNMMI 2023
SNMMI 2023
SNMMI 2023: PSMA PET Prognostic Value for Outcome of Pre-Chemotherapy Post-ARSI CRPC Patients: A Single Center Retrospective Analysis
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Dr. Angela Castellanos Rieger presented the results of an analysis evaluating the prognostic value of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) among castrate-resistant prostate cancer (CRPC) patients in the pre-chemotherapy, post-androgen receptor signaling inhibitor (ARSI) treatment setting.
SNMMI 2023: 68Ga-PSMA PET/CT-Based Multivariate Model for Highly Accurate and Noninvasive Diagnosis of Clinically Significant Prostate Cancer in the PSA Gray Zone
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Dr. Jinhui Yang presented the results of an analysis evaluating the role of 68Ga-PSMA PET/CT-based multivariable modeling for the diagnosis of clinically significant prostate cancer (csPCa) in patients with PSA levels in the 4-10 ng/ml range.
SNMMI 2023: Intraindividual Comparison of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA PET/CT in Patients with mCRPC in a Theranostic Setting
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer radiotracers session. Dr. Jens Kurth presented the results of an intra-individual analysis comparing the performance characteristics of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA PET/CT in metastatic castrate-resistant prostate cancer (mCRPC) patients.
SNMMI 2023: Tumour-to-Kidney Ratio on Pre-Therapeutic PSMA-PET-CT May Be Predictive of the Response [Of Lymphatic and Bone Metastases] to Therapy in mCRPC
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Melanie Hohberg presented the results of an analysis evaluating whether tumor-to-kidney ratio on pre-treatment PSMA-PET/CT was predictive of treatment response in metastatic castrate-resistant prostate cancer (mCRPC) patients.
SNMMI 2023: Personalized PSMA-Directed Molecular RT with Identification of Favorable Genomic and Post-Therapeutic Radiomic Parameters: A Real-World Experience Post-FDA-Approval of Lu-177 PSMA-617 from a Single Comprehensive U.S. Theranostic Center
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Harshad Kulkarni discussing personalized PSMA-directed molecular radiotherapy with identification of favorable genomic and post-therapeutic radiomic parameters. With the publication of the VISION trial, the FDA and EMA subsequently approved the use of Lu-177 PSMA-617 in the third line setting of metastatic castration-resistant prostate cancer (mCRPC) treatment.1
SNMMI 2023: Safety and Efficacy of 177Lu-PSMA-I&T Radioligand Therapy in Octogenarians with mCRPC: Report on 80 Patients over Age of 80
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Isabel Rauscher discussing safety and efficacy of 177Lu-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177 PSMA radioligand therapy is a new treatment option for mCRPC and has received recent FDA approval based on the results of the VISION trial.1
SNMMI 2023: Higher SUV Mean in Baseline 18F-PSMA 1007 PET Is Associated with Longer Survival in Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Thomas Huettmann discussing the impact of higher SUV mean in baseline 18F-PSMA 1007 PET and the association with survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T.
SNMMI 2023: PSMA PET/CT for Prostate Cancer Patients After Focal Therapy: A Single Center Retrospective Analysis
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Dr. Mahbod Jafarvand presented the results of a single center, retrospective analysis evaluating PSMA-PET/CT for prostate cancer patients following focal therapy.
SNMMI 2023: Early Adverse Events, Emergency Room Visits and Hospitalizations After PSMA Based RLT: a Retrospective Analysis from Real World Theranostics Practice
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Dr. Ahmad Abdelrazek presented the results of a real-world, retrospective analysis evaluating the early adverse events, emergency room visits, and hospitalizations following prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT).
SNMMI 2023: Associations Between Antihormonal-Treatment Status and ⁶⁸Ga-PSMA-HBED-CC PET Biodistribution
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a prostate cancer session. Dr. Kilian Kluge presented the results of an analysis evaluating the effects of anti-hormonal treatment status on ⁶⁸Ga-PSMA-HBED-CC positron emission tomography (PET) biodistribution in prostate cancer patients.
SNMMI 2023: 89Zr-DFO-Girentuximab PET/CT Imaging Can Accurately Detect Clear Cell Renal Cell Carcinoma Primary and Secondary Lesions in Patients with Renal Masses at Conventional Imaging, Results from ZIRCON Phase 3 Study
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Dr. Jeremie Calais presented the results of the ZIRCON phase 3 trial (NCT03849118) that evaluated the test performance characteristics of 89Zr-DFO-girentuximab PET/CT imaging for the accurate detection of clear cell renal cell carcinoma (RCC) primary and secondary lesions in patients with renal masses detected via conventional imaging.
SNMMI 2023: Zirconium-Labelled Girentuximab (89Zr-TLX250-CDx) PET/CT Imaging for Non-Invasive Diagnosis of Clear Cell Renal Cell Carcinoma: Results from the UCLA Cohort of the ZIRCON Trial
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Following his earlier presentation of the ZIRCON phase 3 study results in the overall cohort, Dr. Calais next presented results from the UCLA cohort of this trial.
SNMMI 2023: Comparison of 68Ga-PSMA and 18F-FDG PET/CT in Metastatic Workup of Renal Cell Carcinoma (RCC)
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Dr. Saurav Jha presented the results of an analysis comparing 68Ga-PSMA-PET/CT and 18F-FDG-PET/CT in the metastatic work up of renal cell carcinoma (RCC).
SNMMI 2023: Early Response Assessment to Tyrosine Kinase Inhibitors in Metastatic Clear Cell Cancer Using 68Ga-PSMA-11 PET and CECT: A Comparison Study
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Dr. Piyush Aggarwal presented the results of an analysis comparing early response assessment to tyrosine kinase inhibitors (TKIs) in metastatic clear cell renal cell cancer (RCC) using 68Ga-PSMA-11-PET versus contrast-enhanced computed tomography (CT).
SNMMI 2023: PET Evaluation of Changes in c-MET Expression in Metastatic Renal Cell Carcinoma Under Therapy with Cabozantinib
- Details
(UroToday.com) The 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Chicago, IL between June 24th and 27th, 2023 was host to a session on urologic malignancies. Dr. Lena Unterrainer presented the results of an analysis evaluating changes in c-MET expression in metastatic renal cell carcinoma (RCC) patients using c-MET-targeted PET imaging.
SNMMI 2023: Post-Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies to Assess the Impact of Urinary Activity on Interpretation of 18F-rhPSMA-7.3 PET/CT
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Phillip Kuo discussing a post-hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies to assess the impact of urinary activity on interpretation of 18F-rhPSMA-7.3 PET/CT. Radiohybrid (rh) 18F-rhPSMA-7.3 is a novel high affinity PSMA-targeting PET radiopharmaceutical currently under investigation as a diagnostic imaging tool for patients with prostate cancer:
SNMMI 2023: Phase I/II Clinical Trial of 177Lu-DGUL in mCRPC Patients: Preliminary Results of Safety, Dosimetry, and Efficacy
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Minseok Suh discussing preliminary results of safety, dosimetry, and efficacy in a phase I/II clinical trial of 177Lu-DGUL in metastatic castration-resistant prostate cancer (mCRPC) patients.
SNMMI 2023: Predictive Features of 18F-DCFPyL PSMA PET/MRI in High-Risk Prostate Cancer Patients Treated with Neoadjuvant Chemohormonal Therapy Prior to Radical Prostatectomy
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Muheon Shin discussing predictive features of 18F-DCFPyL PSMA PET/MRI in high-risk prostate cancer patients treated with neoadjuvant chemohormonal therapy prior to radical prostatectomy. Neoadjuvant chemohormonal therapy followed by cytoreductive radical prostatectomy is a novel and emerging therapeutic approach in patients with newly diagnosed high-risk primary prostate cancer with oligometastatic disease.
SNMMI 2023: Re-SPECT: Patient Outcomes Following a Response Biomarker Guided Approach to Treatment Using 177Lu-PSMA-I&T in Men with mCRPC
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Andrew Nguyen discussing Re-SPECT, a study assessing patient outcomes following a response biomarker guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate resistant prostate cancer (mCRPC). 177LuPSMA is an effective treatment in mCRPC with trials, such as VISION and TheraP, adopting a standardized dose interval.1,2
SNMMI 2023: Dual PSMA/FDG PET/CT for Assessing Eligibility and Predicting Response in mCRPC Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: A Post-VISION Analysis
- Details
(UroToday.com) The 2023 SNMMI annual meeting included a prostate cancer session, featuring a presentation by Dr. Anushna Babu discussing dual PSMA/FDG PET/CT for assessing eligibility and predicting response in mCRPC patients undergoing 177Lu-PSMA-617 radioligand therapy. Even though baseline PSMA expression is a requisite to successful radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC), there is a subset of patients who do not respond to therapy.